Lupus & antiphospholipid syndrome
2023 ACR/EULAR classification criteria in existing research cohorts: an international study
Authors' conclusion
When applying the new APS criteria to our research cohorts, not-negligible differences exist in patients' classification.
Study context
- Population
- Consecutive patients persistently positive for at least one aPL in the last three years, two large research cohorts
- Participants
- 249 participants2 research cohorts
- Exposure
- 2023 ACR/EULAR APS classification criteria vs Sydney criteria
- APS (Sydney)n = 185
- aPL carriers (Sydney)n = 64
- Outcome
- Classification of patients by the 2023 ACR/EULAR APS criteria vs Sydney criteria
Methodological detailsinternational, two research cohorts, consecutive patients
- International
- Two research cohorts
- Consecutive patients
Main finding
As reported in the abstract
Patients with APS per Sydney criteria failing to reach the composite score of the 2023 ACR/EULAR criteria
Failed to reach the 2023 criteria composite score (of 185 Sydney APS)
90
48.7%
Thrombotic APS per Sydney criteria
decreased from 47.3% to 34.9%
Pregnancy morbidity APS
decreased from 26.9% to 3.2%
aPL carriers
increased from 26% to 61%
Observational data: associations, not effects.
Further findings
- Patients failing criteria who fulfilled new APS criteria at follow-up after additional clinical manifestation — APS (Sydney)
- 35.6%
- Patients failing criteria who fulfilled new APS criteria at follow-up after additional clinical manifestation: 32 of 90
First index event among Sydney APS patients
- Venous thrombosis
- 55 (29.8%)
- Arterial thrombosis
- 63 (34%)
- Pregnancy morbidity
- 67 (36.2%)
Original publication
2023 ACR/EULAR classification criteria in existing research cohorts: an international study. Rheumatology (Oxford). Published 30 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →